Coherus Oncology, Inc.

Biotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

2 drugs in development

Phase 21

Phase 11

By Therapeutic Area

top 1

Oncology

2100%

R&D Momentum

30/100

Pipeline Velocity

0/100

Trial Completion Rate

83/100

Pipeline Concentration

100/100

Pipeline Freshness

74/100

Activity

Recent Activity

Last 14 days

Jul 7, 2026

Recruiting

A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors

Earlier

Jun 30, 2026TrialA Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Apr 1, 2025TrialA Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Feb 15, 2025TrialA Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

Dec 20, 2024TrialA Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Nov 1, 2024TrialA Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

Oct 27, 2023FDALOQTORZI — LOQTORZI

Apr 26, 2023TrialStudy to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

4 more events

Jan 17, 2022TrialStudy of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Aug 1, 2020TrialAn Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca

Apr 22, 2020TrialStudy of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Mar 16, 2020TrialStudy of SRF617 in Patients With Advanced Solid Tumors

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Oncology

Hepatocellular Carcinoma

Casdozokitug

Solid Tumor

CHS-114

Oncology

Hepatocellular Carcinoma

CasdozokitugPhase 2

Solid Tumor

CHS-114Phase 1

Regulatory

Regulatory Timeline

20231 event

FDAOct 27

LOQTORZI — LOQTORZI

Application BLA761240 (BLA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)